NeoGenomics, Inc. Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

FT. MYERS, Fla., April 25, 2013 -- /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the first quarter of 2013.

First Quarter 2013 Highlights:

Test Volume Growth of 19%



Help employers find you! Check out all the jobs and post your resume.